ECSP22049906A - Agonistas del tlr7 - Google Patents

Agonistas del tlr7

Info

Publication number
ECSP22049906A
ECSP22049906A ECSENADI202249906A ECDI202249906A ECSP22049906A EC SP22049906 A ECSP22049906 A EC SP22049906A EC SENADI202249906 A ECSENADI202249906 A EC SENADI202249906A EC DI202249906 A ECDI202249906 A EC DI202249906A EC SP22049906 A ECSP22049906 A EC SP22049906A
Authority
EC
Ecuador
Prior art keywords
tlr7 agonists
diseases
tlr7
agonists
cancer
Prior art date
Application number
ECSENADI202249906A
Other languages
English (en)
Inventor
James Richard Appleman
Stephen E Webber
Original Assignee
Primmune Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Primmune Therapeutics Inc filed Critical Primmune Therapeutics Inc
Publication of ECSP22049906A publication Critical patent/ECSP22049906A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/16—Purine radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
    • A61K31/708—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid having oxo groups directly attached to the purine ring system, e.g. guanosine, guanylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Engineering & Computer Science (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Virology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Saccharide Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

La presente invenci?n se refiere a agonistas de TLR7 seg?n la f?rmula I y su uso en el tratamiento de enfermedades como el c?ncer y las enfermedades infecciosas.
ECSENADI202249906A 2019-11-26 2022-06-24 Agonistas del tlr7 ECSP22049906A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201962940622P 2019-11-26 2019-11-26

Publications (1)

Publication Number Publication Date
ECSP22049906A true ECSP22049906A (es) 2022-07-29

Family

ID=75974715

Family Applications (1)

Application Number Title Priority Date Filing Date
ECSENADI202249906A ECSP22049906A (es) 2019-11-26 2022-06-24 Agonistas del tlr7

Country Status (18)

Country Link
US (3) US11692005B2 (es)
EP (1) EP4065155A4 (es)
JP (1) JP7777870B2 (es)
KR (1) KR20220150879A (es)
CN (1) CN115427063A (es)
AU (1) AU2020391487A1 (es)
BR (1) BR112022010165A2 (es)
CA (1) CA3163093A1 (es)
CL (1) CL2022001377A1 (es)
CO (1) CO2022008835A2 (es)
CR (1) CR20220282A (es)
EC (1) ECSP22049906A (es)
IL (1) IL293293A (es)
MX (1) MX2022006307A (es)
PE (1) PE20221324A1 (es)
PH (1) PH12022551280A1 (es)
TW (1) TWI867097B (es)
WO (1) WO2021108649A1 (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114917228B (zh) * 2022-06-07 2023-09-26 广西中医药大学 一种用于预防性治疗狂犬病的药方及其制备方法与应用

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5476659A (en) 1982-11-09 1995-12-19 The Scripps Research Institute Cancerous B cell treatment using substituted nucleoside derivatives
US5011828A (en) 1985-11-15 1991-04-30 Michael Goodman Immunostimulating guanine derivatives, compositions and methods
US5136030A (en) 1988-05-05 1992-08-04 Scripps Clinic And Research Foundation Immunostimulating guanine derivatives, compositions and methods
US5093319A (en) 1989-10-31 1992-03-03 Pfizer Hospital Products Group, Inc. Use of derivatives of chitin soluble in aqueous solutions for preventing adhesions
AU5845594A (en) 1992-11-13 1994-06-08 Scripps Research Institute, The Cancerous b cell treatment using substituted nucleoside derivatives
US5441942A (en) * 1994-05-27 1995-08-15 The Scripps Research Institute 2'3'-dideoxy-2',3'-didehydro-7,8-disubstituted guanosines and their immunostimulative effect
HUP0001186A3 (en) 1996-10-16 2002-04-29 Icn Pharmaceuticals Inc Costa Purine l-nucleosides,analogs and pharmaceutical compositions thereof
KR100789162B1 (ko) 1999-11-12 2007-12-28 파마셋 인코포레이티드 2'-데옥시-ｌ-뉴클레오사이드의 합성
JP2003523978A (ja) 2000-02-18 2003-08-12 シャイアー・バイオケム・インコーポレイテッド ヌクレオシドアナログを用いるｆｌａｖｉｖｉｒｕｓ感染の処置もしくは予防するための方法
ATE491459T1 (de) 2000-10-18 2011-01-15 Pharmasset Inc Modifizierte nukleoside zur behandlung von virusinfektionen und abnormaler zellulärer proliferation
ES2342069T4 (es) 2003-09-05 2011-01-26 Anadys Pharmaceuticals, Inc. Ligandos de tlr7 para el tratamiento de la hepatitis c.
PL1824482T3 (pl) * 2004-12-17 2014-07-31 Anadys Pharmaceuticals Inc 3,5-Dipodstawione oraz 3,5,7-tripodstawione związki 3H-oksazolo- oraz 3H-tiazolo[4,5-d]pirymidyn-2-onowe i ich proleki
KR20100066512A (ko) 2007-08-15 2010-06-17 이데라 파마슈티칼즈, 인코포레이티드 톨 유사 수용체 조절자
JP5600104B2 (ja) 2008-08-01 2014-10-01 ベンティアールエックス ファーマシューティカルズ， インコーポレイテッド Ｔｏｌｌ様受容体アゴニスト処方物およびその使用
WO2010111290A1 (en) 2009-03-23 2010-09-30 University Of Utah Research Foundation Methods and compositions related to modified guanine bases for controlling off-target effects in rna interference
JP2014532799A (ja) 2011-11-09 2014-12-08 アセンド・バイオファーマシューティカルズ・リミテッド 免疫調節結合体
WO2016004876A1 (en) 2014-07-09 2016-01-14 Shanghai Birdie Biotech, Inc. Anti-pd-l1 combinations for treating tumors
KR102557560B1 (ko) 2014-12-08 2023-07-20 에프. 호프만-라 로슈 아게 바이러스 감염의 치료 또는 예방을 위한 3-치환된 5-아미노-6H-티아졸로[4,5-d]피리미딘-2,7-다이온 화합물
MA52701A (fr) * 2015-03-16 2021-03-31 Hoffmann La Roche Traitement combiné avec un agoniste tlr7 et un inhibiteur d'assemblage de capside du virus de l'hépatite b
CN115554406A (zh) 2016-01-07 2023-01-03 博笛生物科技有限公司 用于治疗肿瘤的抗-cd20组合
PE20191474A1 (es) * 2016-12-20 2019-10-16 Astrazeneca Ab Compuestos de amino-triazolopiridina y su uso en el tratamiento del cancer
US11059824B2 (en) * 2018-05-25 2021-07-13 Primmune Therapeutics, Inc. Substituted purines as TLR7 agonists

Also Published As

Publication number Publication date
EP4065155A1 (en) 2022-10-05
CL2022001377A1 (es) 2023-04-10
KR20220150879A (ko) 2022-11-11
WO2021108649A1 (en) 2021-06-03
US11692005B2 (en) 2023-07-04
EP4065155A4 (en) 2023-11-29
BR112022010165A2 (pt) 2022-08-09
CA3163093A1 (en) 2021-06-03
US20210155652A1 (en) 2021-05-27
US20260055132A1 (en) 2026-02-26
US12187759B2 (en) 2025-01-07
IL293293A (en) 2022-07-01
TWI867097B (zh) 2024-12-21
JP7777870B2 (ja) 2025-12-01
MX2022006307A (es) 2022-08-22
CN115427063A (zh) 2022-12-02
AU2020391487A1 (en) 2022-07-07
TW202134240A (zh) 2021-09-16
CO2022008835A2 (es) 2022-07-19
US20240116974A1 (en) 2024-04-11
PE20221324A1 (es) 2022-09-09
PH12022551280A1 (en) 2024-01-08
CR20220282A (es) 2022-11-28
JP2023503996A (ja) 2023-02-01

Similar Documents

Publication Publication Date Title
MX2021011209A (es) Novedosos inhibidores de molécula pequeña de factores de transcripción tead.
CO2020010956A2 (es) Composiciones y métodos para el tratamiento del cáncer y de trastornos inmunitarios usando bacterias de veillonella
ECSP20020410A (es) Inhibidores de la ectonucleótido pirofosfatasa-fosfodiesterasa 1 (enpp-1) y usos de los mismos
CO2021008224A2 (es) Inhibidores de kif18a
DOP2019000005A (es) 3-metil pirazinas 2,5-disustituidas y 3-metil pirazinas 2,5,6-trisustituidas como inhibidores alostéricos de shp2
ECSP20033467A (es) Compuestos macrocíclicos para tratar enfermedades
MX2022009596A (es) Anticuerpos anti-ror1 y composiciones.
MX386935B (es) Profármacos de fumaratos y su uso en el tratamiento de diferentes enfermedades.
MX2023004920A (es) Compuestos inhibidores de la proteina 6 del linfoma de linfocitos b (bcl6).
ECSP20082988A (es) Agonistas de tlr7
MX2020003495A (es) Derivados de acido boronico y sintesis de los mismos.
CO2020003475A2 (es) Sulfonas y sulfóxidos bicíclicos y métodos de uso de los mismos
ECSP20032718A (es) Polimorfos
DOP2019000221A (es) Derivados de pirazol como inhibidores de bromodominio
MX2017003788A (es) Derivados de nucleósidos sustituidos con 4´-vinilo como inhibidores de la replicación del arn del virus respiratorio sincitial.
ECSP22049906A (es) Agonistas del tlr7
CL2018002368A1 (es) Formulaciones de oritavancina
MX2022003398A (es) Composicion micelar inmunoestimulante.
CR20150641U (es) Composiciones farmacéuticas
MX2020002812A (es) Abx196 para usarse en el tratamiento del cancer de vejiga.
MX2020004871A (es) Derivados de acido cafeico y sus usos.
AR123554A1 (es) Composiciones y métodos para el tratamiento de la inflamación usando prevotella histicola
AR114246A1 (es) Composición y métodos para tratar cáncer y trastornos inmunes usando bacterias veillonella